Artificial Intelligence Company Reveals Major Insights For Bipolar Disorder Disorder Pathways

BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW), a leader in AI-driven drug discovery, has announced advancements in its ongoing collaboration with the Lieber Institute for Brain Development (LIBD). This collaboration has yielded pivotal insights into the molecular pathways associated with bipolar disorder (BD) and identified new candidate drug targets. These findings build upon the progress detailed in their May 16, 2024 release, further narrowing down the gene networks most involved in BD, thus paving the way for more targeted and effective research and treatment options. $BullFrog AI(BFRG.US)$